NVO Novo Nordisk A/S

46.5
-0.27  -1%
Previous Close 46.77
Open 46.42
Price To Book 15.4
Market Cap 111416015868
Shares 2,396,043,352
Volume 2,974,345
Short Ratio 1.91
Av. Daily Volume 1,755,434

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Final PIONEER trial data released November 23, 2018. Primary inferiority endpoint met. Reduction in MACE did not reach statistical significance.
Semaglutide - oral - PIONEER
Type 2 diabetes
Phase 2 Explorer 4 data due 4Q 2018.
Concizumab - explorer
Hemophilia A
Approval announced August 25, 2017.
Victoza (liraglutide)
Type 2 diabetes
Approved September 29, 2017.
Fiasp (fast-acting insulin aspart)
Type 1 and type 2 diabetes
Phase 2 AGHD data noted height velocity did not differ significantly compared to Norditropin.
Somapacitan (NN8640) - REAL 3
Adult Growth Hormone Deficiency (AGHD)
Phase 2 data released June 23, 2017 with Phase 3 trial to commence 2018.
Semaglutide (NN9536)
Obesity
Phase 2 ongoing.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
Approval announced December 5, 2017.
Semaglutide
Type 2 diabetes
Approval announced May 31, 2017.
Nonacog beta pegol
haemophilia B
BLA filing announced February 27, 2018.
N8-GP
Hemophilia A
Phase 2 trial to commence before end of 2018.
LAI287
Type 2 diabetes
Phase 2 trial to commence early 2019.
AM833
Obesity

Latest News

  1. Novo Nordisk announces another $22M investment in Clayton
  2. Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial
  3. The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources
  4. Novo Nordisk A/S (NVO): Hedge Fund Sentiment Going Nowhere
  5. Novo Nordisk Continues Its Balancing Act
  6. Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales
  7. [$$] Danish Insulin Maker Novo Nordisk Cuts Jobs, Shifts R&D Spending
  8. Novo Nordisk (NVO) Q3 2018 Earnings Conference Call Transcript
  9. Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure
  10. Novo Nordisk: 3Q Earnings Snapshot
  11. Novo Nordisk earnings miss expectations amid currency headwinds
  12. Q3 Earnings Preview For Novo Nordisk
  13. Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S — Discovering Underlying Factors of Influence
  14. What Analysts Recommend for Novartis after Q3 Earnings
  15. How Novartis’s Alcon Performed in Third Quarter
  16. 5 Undervalued Companies With Predictable Businesses
  17. How Novartis’s Innovative Medicines Business Performed in Q3
  18. Novo Nordisk (NVO) Faces Pricing Pressure and Competition
  19. Minnesota accuses insulin makers of deceptive drug pricing